Acute Myeloid Leukemia: State of the Art in 2018
|
|
- Alexis Ball
- 5 years ago
- Views:
Transcription
1 Acute Myeloid Leukemia: State of the Art in 2018 Harry P. Erba, MD, PhD Professor, Department of Medicine Director, Leukemia Program Duke University Durham, NC
2 Treatment Paradigm of Adults with AML Fit for intensive chemotherapy Induction chemotherapy CR Consolidation chemotherapy CR Allo HSCT AML Dx Refractory Relapse Salvage Therapy Unfit for intensive chemotherapy Azacitidine Decitabine LD Cytarabine Gemtuzumab ozogamicin response Maintenance
3 Probability ECOG E1900 (Treatment Naïve AML, < Age 60 Years): Overall Survival 1.0 All Patients (N = 647) DNR 90 mg/m 2 /day x 3 + Cytarabine 100 mg/m 2 /day x 7 DNR 45 mg/m 2 /day x course to CR Sibling Donor Allogeneic HSCT High-dose Cytarabine x 2 cycles Observation Gemtuzumab Ozogamicin 6 mg/m 2 x1 Auto HSCT Log Rank P = Induction Treatment DNR 45 mg/m 2 /day DNR 90 mg/m 2 /day N = 327 N = 330 CR 57% CR 71% Month Fernandez HF, et al. N Engl J Med. 2009; 361(13):
4 Benefit of High Dose Daunorubicin in Induction Therapy for Adults < Age 60 Years with FLT3 ITD + AML Overall Survival DNR 90 DNR 45 CR rate 70% 48% Median OS 15.2 mo 10.1 mo OS at 4 years 28% 17% Luskin MR, et al. (Update ECOG 1900). Blood 2016
5 No Benefit of Daunorubicin 90 vs 60 mg/m 2 in Induction Therapy for Younger AML Patient CR rate DA60 75% DA90 73% Burnett A, et al. (UK NCRI AML 17) Blood. April 1, 2015
6 Higher Daunorubicin Exposure Benefits FLT3 Mutated AML ITD and TKD At 3 years DNR 90 DNR 60 HR P CIR 44% 60% RFS 45% 33% OS 54% 34% Burnett A, et al. (UK NCRI AML 17). Blood 2016; 128 (3): 449.
7 S1203: Overall survival (N = 261, deaths = 99) IA (N = 261, deaths = 96) IA+V (N = 216, deaths = 88) IA+V versus IA p value = 0.60 IA+V versus 7+3 p value = 0.67 IA versus 7+3 p value = 0.92 Garcia-Manero G. et al. ASH Years since randomization
8 Fractionated GO Improves EFS in Adult AML Patients 280 patients with treatment naïve de novo AML, age % intermediate risk karyotype, 3% favorable risk, 18% FLT3 ITD+ Induction: DNR 60 mg/m 2 /d x 3 and Ara-C 200 mg/m 2 /d x 7 +/- GO 3 mg/m 2 d 1, 4, 7 Consolidation: DNR 60 mg/m 2 d 1 and Ara-C 1 gram/m 2 q12 hr d 1-4 +/- GO 3 mg/m 2 d 1 DA DA+GO CR rate 75% 81% EFS, 2 years 17% 41% RFS, 2 years 23% 50% OS, median 19 months 34 months Longer duration of both neutropenia and thrombocytopenia in DA+GO 3 cases of VOD/SOS, 2 fatal. No VOD following allo HSCT (only 6 pt) Castaigne S, et al. Leukemia 2012;379:
9 Addition of Fractionated GO to Induction and Consolidation Improves Event-free and Overall Survival EFS OS Castaigne S, et al. Lancet 2012; 379:
10 Forest Plot of Event Free Survival (ALFA 0701) Castaigne S, et al. Lancet 2012; 379:
11 RATIFY (CALGB 10603): Chemotherapy + Midostaurin or Placebo Newly Diagnosed Patients < 60 Years With FLT3-Mutated AML Induction Consolidation x 4 Maintenance ND AML FLT3-ITD / TKD+ (Mutation Screening Within 48 Hours) Age years 3277 subjects screened; 896 FLT3 mutation positive; 717 randomized (80% selection bias) n = 717 R 1:1 Daunorubicin Cytarabine plus Placebo Daunorubicin Cytarabine plus Midostaurin High-Dose Cytarabine plus Placebo High-Dose Cytarabine plus Midostaurin Placebo Midostaurin Collaboration with 13 international cooperative groups; 225 sites from 17 countries Alliance, SWOG, ECOG, NCIC CTG, GIMEMA, EORTC, AMLSG, SAL, OSHO, PETHEMA, CETLAM 9 academic FLT3 screening laboratories worldwide Stone RM, et al. N Engl J Med. 2017;377:
12 RATIFY (CALGB 10603): Overall Survival Median OS OS Subgroup Analysis 51% 44% Toxicity No difference in early mortality Higher rate of rash and GI toxicity with mido Stone RM, et al. N Engl J Med. 2017;377:
13 Phase 3 Study of CPX-351 Versus 7+3 in Older Patients With Newly Diagnosed High-Risk AML Key eligibility Previously untreated Aged years Able to tolerate intensive therapy PS 0-2 CPX-351 n = 153 Stratifications Therapy-related AML AML with history of MDS with and without prior HMA therapy AML with history of CMML De novo AML with MDS karyotype Aged years Aged years 7+3 n = 156 Induction CPX mg/100 mg per m 2 IV days 1, 3, 5 Cytarabine 100 mg/m 2 /day x 7 plus daunorubicin 60 mg/m 2 /day x 3 Lancet JF et al. J Clin Oncol. 2018; 36: Reinduction CPX-351 days 1 and 3 OR 5+2 Induction (1-2 cycles) Primary endpoint: Overall survival Patients in CR or CRi: Consolidation (1-2 cycles) Follow-up Death or 5 years Consolidation CPX mg/65 mg per m 2 IV days 1, 3 Cytarabine 100 mg/m 2 /day x 5 plus daunorubicin 60 mg/m 2 /day x 2
14 Patients, % Patients, % CPX-351 Versus 7+3 for Secondary AML: 30-Day and 60-Day Mortality Rates % % % % CPX Deaths 30 Days 0 CPX Deaths 60 Days Deaths Secondary to Progressive AML Deaths Secondary to Adverse Event Lancet JE et al. J Clin Oncol. 2016; 34(suppl): 7000.
15 Phase 3 Study of CPX-351 Vs 7+3 in High-Risk AML: Response Rate CPX-351 (n = 153) 7+3 (n = 156) 60 P =.016 P = % Patients, % a % 25.6% 33.3% 0 Odds ratio (95% CI) CR CR + CRi 1.69 (1.03, 2.78) 1.77 (1.11, 2.81) Lancet JF et al. J Clin Oncol. 2018; 36:
16 Survival, % CPX-351 Improves Survival Among Older, High-Risk AML Kaplan-Meier Curve for OS: ITT Analysis Population Lancet JF et al. J Clin Oncol 2018; 36:
17 Delayed Recovery of ANC and Platelet Count with CPX-351 Compared with 7+3 in Older, High Risk AML Patients receiving 1 induction ANC 500/mcL Platelets 50,000/mcL CPX CPX n = 58 n = 34 n = 58 n = 34 Median, days Patients receiving 2 inductions n = 15 n = 18 n = 15 n = 18 Median, days Lancet JE et al. J Clin Oncol. 2016; 34(suppl): 7000.
18 Induction Therapy for Adult AML (Fit for chemotherapy, age agnostic) Prior leukemogenic therapy Antecedent MDS or MDS/MPN Cytogenetic Risk FLT3 mutation CBF AML Intermediate risk FLT3 Mutated Secondary AML Poor risk karyotype DNR / Ara-C + GO DNR / AraC + midostaurin CPX 351
19 Barriers to Incorporating Recently Approved Agents into AML Therapy Labeled indication may be too restrictive or too permissive Extrapolation of clinical trial data to other populations History of drug development Value of EFS benefit Clinician preferences/beliefs regarding AML therapy Cost of new agents and inpatient payments Lack of data on combination therapies TAT for cytogenetic and mutation analysis
20 Treatment Paradigm of Adults with AML Fit for intensive chemotherapy Induction chemotherapy CR Consolidation chemotherapy CR Allo HSCT AML Dx Refractory Relapse Salvage Therapy Unfit for intensive chemotherapy Azacitidine Decitabine LD Cytarabine Gemtuzumab ozogamicin response Maintenance
21 AML-001 Study of Aza vs CCR in Older AML: Overall Survival a ITT population. b Median follow-up for OS was 24.4 months, with 193 deaths in AZA arm (80.1%) and 201 deaths in the CCR arm (81.4%). c Stratified by ECOG PS and cytogenetic risk. Dombret H et al. Blood. 2015; 126:
22 GO vs BSC in Older Treatment Naïve AML: EORTC/GIMEMA AML 19 All Patients Favorable/Intermediate Risk Karyotype Poor Risk Karyotype GO 6 mg/m 2 day 1, 3 mg/m 2 day 8 followed by 2 mg/m 2 q month x 8 GO CR rate 27% Median overall survival: GO 4.9 months, BSC 3.6 months Decreased survival benefit with lower CD33 expression Amadori S et al. J Clin Oncol 2016; 34: 972
23 Phase Ib VEN + HMA: Patient Characteristics Characteristic N=145* Median age (range), years 74 (65 86) Male, n (%) 81 (56) ECOG Performance Score, n (%) 0 32 (22) 1 90 (62) 2 23 (16) Baseline bone marrow blasts, n (%) 30% 44 (30) 31 50% 48 (33) >50% 53 (37) Median months on study (range) 8.9 ( ) Baseline hydroxyurea use, n (%) 14 (10) * Includes 11 patients treated with 1200 mg of venetoclax Cytogenetic risk groups defined in 2014 NCCN guidelines, version 2 Site reported data; to be confirmed by central laboratory Key Characteristic N=145* Age 75 years, n (%) 62 (43) Cytogenetics, n (%) Intermediate risk 74 (51) Poor risk 71 (49) Mutation, n (%) FLT3 14 (10) IDH 1/2 22 (15) TP53 16 (11) Secondary AML, n (%) 36 (25) Data cutoff was July 7, 2017 median months of follow up was 15.6 DiNardo CD et al. EHA Annual Congress. 2018
24 Phase Ib VEN + HMA in AML: Treatment-Emergent AE AEs in 25% of patients Any grade Grade 3/4 Any event, n (%) 145 (100) 141 (97) Nausea 88 (61) 2 (1) Diarrhea 76 (52) 7 (5) Constipation 70 (48) 2 (1) Febrile neutropenia 63 (43) 63 (43) Fatigue 54 (37) 8 (6) Hypokalemia 49 (34) 15 (10) Decreased appetite 48 (33) 3 (2) Decreased WBC count 45 (31) 45 (31) Vomiting 44 (30) 0 Platelet count decreased 42 (30) 35 (24) Anemia 40 (28) 36 (25) Cough 41 (28) 0 Peripheral edema 41 (28) 0 No Clinical or Laboratory Evidence of TLS Serious AEs in 3% of patients N = 145 Any event, n (%) 102 (70) Febrile neutropenia 46 (32) Pneumonia 17 (12) Bacterial Infection 9 (6) Lung Infection 7 (5) Sepsis 6 (4) Hypotension 5 (3) Mental Status Changes 4 (3) Gastrointestinal Hemorrhage 4 (3) Mucosal Inflammation 4 (3) Patient Disposition Deaths, n (%) N=145* 30 days after Ven start 5 (3) 60 days after Ven start 11 (8) DiNardo CD et al. European Hematology Association Congress 2018, Stockholm, Sweden.
25 R a te o f R e s p o n s e (% ) Phase Ib VEN + HMA in AML: Response Rates by Treatment Patients (%) with CR/CRi shown at the top of each bar * Includes 11 patients that received 1200 mg venetoclax A ll D o s e s * V e n m g V e n m g A z a D e c A z a D e c N = n = 2 9 n = 3 1 n = 3 7 n = 3 7 O t h e r R D M L F S P R C R i C R DiNardo CD et al. European Hematology Association Congress 2018, Stockholm, Sweden.
26 R a te o f R e s p o n s e (% ) Phase Ib VEN + HMA in AML: Response Rates by Patient Subgroups C y t o g e n e t ic R is k A M L A g e Patients (%) with CR/CRi shown at the top of each bar O t h e r R D M L F S P R C R i C R In t r m e d P o o r D e n o v o 2 o < n = 7 4 n = 7 1 n = n = 3 6 n = 8 3 n = 6 2 DiNardo CD et al. European Hematology Association Congress 2018, Stockholm, Sweden.
27 O v e r a ll S u r v iv a l (% ) Phase Ib VEN + HMA in AML: Overall Survival Median Months of Survival (95% CI) Ven 400 mg NR (11.0 NR) All Patients 17.5 (12.3 NR) Ven 800 mg 17.5 (10.3 NR) V e n m g A ll P a tie n t s V e n m g P a t ie n t s a t R is k A ll p a t ie n t s M o n t h s S in c e F ir s t D o s e V e n m g V e n m g DiNardo CD et al. European Hematology Association Congress 2018, Stockholm, Sweden. 2
28 Standard Therapy for Unfit AML Have single agent HMA or LoDAC been replaced by venetoclax combination based on results of phase Ib studies? If so, why?
29 Treatment Paradigm of Adults with AML Fit for intensive chemotherapy Induction chemotherapy CR Consolidation chemotherapy CR Allo HSCT AML Dx Refractory Relapse Salvage Therapy Unfit for intensive chemotherapy Azacitidine Decitabine LD Cytarabine Gemtuzumab ozogamicin response Maintenance
30 Phase III Study of Elacytarabine vs Investigator Choice for Rel/Ref AML Prior Regimen 1 9% 2 60% >3 31% Investigator Choice: HiDAC MEC FLAG FLAG/IDA LoDAC Azacitidine Decitabine Hydroxyurea Supportive care Roboz G et al. J Clin Oncol. 2014; 32:
31 Enasidenib in Patients With IDH2 Mutations: Responses Parameter Relapsed or Refractory AML Enasidenib 100 mg/d (n = 109) All Doses (N = 176) ORR, % [n/n] 95% CI 38.5% (42/109) [ ] 40.3% (71/176) [ ] Best response CR, n (%) [95% CI] 22 (20.2) [ ] 34 (19.3) [ ] CRi or CRp, n (%) 7 (6.4) 12 (6.8) PR, n (%) 3 (2.8) 11 (6.3) MLFS, n (%) 10 (9.2) 14 (8.0) SD, n (%) 58 (53.2) 85 (48.3) PD, n (%) 5 (4.6) 9 (5.1) NE, n (%) 2 (1.8) 3 (1. 7) Time to first response (mo), median (range) 1.9 ( ) 1.9 ( ) Duration of response (mo), median [95%CI] 5.6 [ ] 5.8 [ ] Time to CR (mo), median (range) 3.7 ( ) 3.8 ( ) Duration of CR (mo), median [95%CI] 8.8 [5.3, NR] 8.8 [6.4, NR] Overall response by IDH mutation type: R140Q 36% / R172K 42% Stein EM et al. Blood. 2017;130:
32 Enasidenib in R/R AML Patients With IDH2 Mutations: OS R/R AML Patients Treated at all Doses (N = 176) Median Overall Survival : 9.3 months (95% CI 8.2, 10.9) Stein EM et al. Blood. 2017;130:
33 Enasidenib in R/R IDH2m+ AML: OS by Best Response R/R AML Patients (N =176) Median OS (95% CI) CR 19.7 mo (11.6-NE) Non-CR Response 13.8 mo ( ) No Response 7.0 mo ( ) Stein EM et al. Blood. 2017;130:
34 Enasidenib-induced Differentiation of IDH2-R140Q Clone Screening 37% BM Blasts Cycle 1 d 15 Evidence of Cellular Differentiation Cycle 3 d 1 4% BM Blasts Blasts Promyelocytes Mature Granulocytes Lymphocytes Stein EM et al. Blood. 2017;130:
35 IDH Differentiation Syndrome (IDH-DS): Analysis of the Phase I/II Enasidenib Study 33 of 281 (11.7%) of enasidenib-treated patients had possible/probable IDH-DS Fathi A et al. JAMA Oncol. 2018; 4(8):
36 2-HG ng/ml midh2 VAF IDH2 Inhibition: 2-HG, VAF, and Response 1.0x10 5 Baseline 2-HG levels and baseline midh2 VAF were similar for responding and nonresponding patients 80 Number of Patient Samples 1.0x x x x10 1 CR R NR R140 R172 Plasma 2-HG (ng/ml) at baseline in 125 efficacy-evaluable R/R AML patients with baseline 2-HG data Amatangelo MD, et al. Blood. 2017;130: PM BM CR R140 PM BM R R PM BM NR NR R172 Baseline midh2 VAF from PB or BM in R/R AML patient samples
37 Co-mutational Burden and N-RAS Mutation are Associated with Lack of Response to Enasidenib in Relapsed / Refractory IDH2m+ AML Amatangelo MD, et al. Blood. 2017;130:
38 Ivosidenib in R/R IDH1m AML: Baseline Demographics Characteristic R/R AML 500 mg (n=179) Characteristic R/R AML 500 mg (n=179) Women / men, n 89 / 90 Age in years, median (range) Age category, n (%) < to < ECOG PS at baseline, n (%) De novo AML, n (%) Secondary AML, n (%) 67.0 (18 87) 47 (26.3) 92 (51.4) 40 (22.3) 36 (20.1) 99 (55.3) 42 (23.5) 2 (1.1) 120 (67.0) 59 (33.0) No. of prior therapies, median (range) 2.0 (1 6) Prior AML therapy outcomes, n (%) Relapsed after transplant In 2nd or later relapse Refractory to initial induction/reinduction therapy Relapsed 1 year of initial therapy In first relapse Other Cytogenetic risk status by investigator, n (%) Intermediate Poor Unknown/missing 43 (24.0) 26 (14.5) 106 (59.2) 17 (9.5) 15 (8.4) 5 (2.8) 105 (58.7) 50 (27.9) 24 (13.4) Pollyea D. et al. European Hematology Association Congress 2018, Stockholm, Sweden. Abstract S1560
39 Ivosidenib in R/R IDH1m AML: Adverse Events Leukocytosis Grade 3 leukocytosis (WBC > 100,000) reported in 14/179 patients (8%) Managed with hydroxyurea None were fatal ECG QT prolongation Grade 3 QT prolongation reported in 18/179 patients (10%) Study drug was reduced in 2 patients and held in 13 patients (all grades) None were fatal QT prolonging medications such as antifungals and fluoroquinolone antiinfectives were allowed on study with monitoring IDH differentiation syndrome (IDH-DS) All grade reported in 19/179 patients (10.6%) Resolved in 17 patients Grade 3 IDH-DS in 9 (5.0%) 7/19 IDH-DS patients had co-occurring leukocytosis No instances of IDH-DS led to dose reduction, permanent treatment discontinuation, or death Managed with corticosteroids and diuretics, and hydroxyurea if accompanied by leukocytosis Best response for the 19 patients with IDH-DS: Best Response CR CRh CRi/CRp MLFS SD NE n= Pollyea D. et al. European Hematology Association Congress 2018, Stockholm, Sweden. Abstract S1560
40 Ivosidenib in R/R IDH1m AML: Response R/R AML 500 mg (n=179) CR+CRh rate, n (%) [95% CI] 57 (31.8) [25.1, 39.2] Time to CR/CRh, median (range) months Duration of CR/CRh, median [95% CI] months 2.0 (0.9, 5.6) 8.2 [5.6, 12.0] CR rate, n (%) [95% CI] 43 (24.0) [18.0, 31.0] Time to CR, median (range) months 2.8 (0.9, 8.3) Duration of CR, median [95% CI] months 10.1 [6.5, 22.2] CRh rate, n (%) 14 (7.8) Duration of CRh, median [95% CI] months 3.6 [1.0, 5.5] R/R AML 500 mg (n=179) Overall Response Rate, n (%) [95% CI] 75 (41.9) [34.6, 49.5] Time to first response, median (range) months Duration of response, median [95% CI] months Best response, n (%) 1.9 (0.8, 4.7) 6.5 [5.5, 10.1] CR 43 (24.0) CRi or CRp 21 (11.7) MLFS 11 (6.1) SD 68 (38.0) PD 15 (8.4) NA 21 (11.7) Pollyea D. et al. European Hematology Association Congress 2018, Stockholm, Sweden. Abstract S1560
41 S u r v iv a l p r o b a b ilit y Ivosidenib in R/R IDH1m AML: OS by Best Response 1.0 C R + C R h 0.9 N o n -C R /C R h re s p o n d e rs 0.8 N o n -re s p o n d e rs 0.7 O v e ra ll C e n s o re d O v e r a ll s u r v iv a l (m o n th s ) N u m b e r o f p a tie n ts a t r is k : Months Overall survival, median [95% CI] CR+CRh Non-CR/CRh responders 18.8 [14.2, NE] 9.2 [6.7, 10.8] Non-responders 4.7 [3.7, 5.7] All 9.0 [7.1, 10.0] Overall follow-up, median (range) 15.3 ( ) C R + C R h N o n -C R /C R h r e s p o n d e rs N o n -r e s p o n d e rs Non-CR/CRh responders include CRi, CRp, and MLFS who are not CRh Non-responders = all others including those with best responses of SD, PD, or not evaluable Pollyea D. et al. European Hematology Association Congress 2018, Stockholm, Sweden. Abstract S1560
42 P o s t-b a s e lin e tra n s fu s io n in d e p e n d e n c e, % Ivosidenib in R/R IDH1m AML: Transfusion Independence C R C R h N o n -C R /C R h re s p o n d e rs N o n -re s p o n d e rs O v erall P la te le t (n = 9 1 ) Transfusion independence was observed across all response categories in R/R AML 500 mg Patients Who Were Dependent at Baseline. Post-baseline transfusion independence defined as no transfusion for at least one 56-day period R B C (n = 9 7 ) Pollyea D. et al. European Hematology Association Congress 2018, Stockholm, Sweden. Abstract S1560
43 Ivosidenib in R/R IDH1m AML: Exposure-adjusted Incidence of Febrile Neutropenia and Grade 3 Infections Best response CR CRh Non-CR/CRh responders Nonresponders Overall (n=43) (n=14) (n=18) (n=104) (n=179) All grade febrile neutropenia 2.0 [1.0, 3.8] 3.7 [1.4, 9.8] 6.1 [2.7, 13.5] 12.1 [8.8, 16.5] 5.9 [4.5, 7.6] Grade 3 infections 2.6 [1.5, 4.6] 6.4 [3.1, 13.5] 13.1 [7.6, 22.6] 21.3 [16.8, 27.0] 10.2 [8.4, 12.4] Incidence rate reported as 100 patients / month [95% CI], calculated as total number of specific AEs / total person exposure time in months x 100 * for all patients with the same best overall response Pollyea D. et al. European Hematology Association Congress 2018, Stockholm, Sweden. Abstract S1560
44 Treatment of Rel/Ref AML with IDH Mutations Responses and goals of therapy Chemotherapy vs IDHm inhibitor
45 Thank You!
Kevin Kelly, MD, Phd Acute Myeloid and Lymphoid Leukemias
Kevin Kelly, MD, Phd Acute Myeloid and Lymphoid Leukemias Relevant financial relationships in the past twelve months by presenter or spouse/partner. Speakers bureau: Novartis, Janssen, Gilead, Bayer The
More informationTREATMENT UPDATES IN ACUTE LEUKEMIA. Shannon McCurdy, MD University of Pennsylvania
TREATMENT UPDATES IN ACUTE LEUKEMIA Shannon McCurdy, MD University of Pennsylvania TIMELINE FOR FDA APPROVED AGENTS FOR AML Midostuarin Enasidenib Cytarabine + Daunorubicin (7+3) Gemtuzumab Ozogamicin
More informationAcute Myeloid Leukemia Progress at last
Acute Myeloid Leukemia Progress at last Bruno C. Medeiros, MD September 9, 217 Introduction Mechanisms of leukemogenesis Emerging therapies in AML Previously untreated AML Relapsed and refractory patients
More informationBackground CPX-351. Lancet J, et al. J Clin Oncol. 2017;35(suppl): Abstract 7035.
Overall Survival (OS) With Versus in Older Adults With Newly Diagnosed, Therapy-Related Acute Myeloid Leukemia (taml): Subgroup Analysis of a Phase 3 Study Abstract 7035 Lancet JE, Rizzieri D, Schiller
More informationSummary of Key AML Abstracts Presented at the European Hematology Association (EHA) June 22-25, 2017 Madrid, Spain
Summary of Key AML Abstracts Presented at the European Hematology Association (EHA) June 22-25, 2017 Madrid, Spain EHA 2017 ANNUAL MEETING: ABSTRACT SEARCH PAGE: https://learningcenter.ehaweb.org/eha/#!*listing=3*browseby=2*sortby=1*media=3*ce_id=1181*label=15531
More informationHow the Treatment of Acute Myeloid Leukemia is Changing in 2019
How the Treatment of Acute Myeloid Leukemia is Changing in 2019 Guido Marcucci, M.D. Director, Gehr Family Center for Leukemia Research Chair, Dept. Hematologic Malignancies Translational Science City
More informationNew concepts in the management of elderly patients with AML
New concepts in the management of elderly patients with AML Martha L. Arellano, MD Associate Professor of Hematology/Oncology Director, Hematology & Medical Oncology Fellowship Program Winship Cancer Institute
More informationIDH1 AND IDH2 MUTATIONS
Mutant Isocitrate Dehydrogenase (midh) Inhibitors, Enasidenib or Ivosidenib, in Combination with Azacitidine (AZA): Preliminary Results of a Phase 1b/2 Study in Patients with Newly Diagnosed Acute Myeloid
More informationEnasidenib Monotherapy is Effective and Well-Tolerated in Patients with Previously Untreated Mutant-IDH2 Acute Myeloid Leukemia
Enasidenib Monotherapy is Effective and Well-Tolerated in Patients with Previously Untreated Mutant-IDH2 Acute Myeloid Leukemia Pollyea DA 1, Tallman MS 2,3, de Botton S 4,5, DiNardo CD 6, Kantarjian HM
More informationENASIDENIB IN MUTANT-IDH2 RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (R/R AML): RESULTS OF A PHASE 1 DOSE- ESCALATION AND EXPANSION STUDY
ENASIDENIB IN MUTANT-IDH2 RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (R/R AML): RESULTS OF A PHASE 1 DOSE- ESCALATION AND EXPANSION STUDY Eytan M. Stein, Courtney D. DiNardo, Daniel A. Pollyea, Amir
More informationAcute Myeloid Leukemia
Acute Myeloid Leukemia Pimjai Niparuck Division of Hematology, Department of Medicine Ramathibodi Hospital, Mahidol University Outline Molecular biology Chemotherapy and Hypomethylating agent Novel Therapy
More information[ NASDAQ: MEIP ] Analyst & Investor Event December 8, 2014
[ NASDAQ: MEIP ] Analyst & Investor Event December 8, 2014 Forward-Looking Statements These slides and the accompanying oral presentation contain forward-looking statements. Actual events or results may
More information2/10/2017. Updates in Acute Leukemia Therapy Blood Cancer Incidence in the United States, Leukemia Incidence in the Unites States, 2016
Updates in Acute Leukemia Therapy 2017 Aaron Logan, MD, PhD UCSF Division of Malignant Hematology and Blood and Marrow Transplantation aaron.logan@ucsf.edu @hemedoc Blood Cancer Incidence in the United
More informationNeue zielgerichtete Behandlungsoptionen der neu diagnostizierten FLT3-positiven Akuten Myeloischen Leukämie (AML)
Neue zielgerichtete Behandlungsoptionen der neu diagnostizierten FLT3-positiven Akuten Myeloischen Leukämie (AML) Prof. Hartmut Döhner Klinik für Innere Medizin III, Universitätsklinikum Ulm Midostaurin
More informationIvosidenib (IVO; AG-120) in mutant IDH1 relapsed/refractory acute myeloid leukemia (R/R AML): Results of a phase 1 study
7000 Ivosidenib (IVO; AG-120) in mutant IDH1 relapsed/refractory acute myeloid leukemia (R/R AML): Results of a phase 1 study Daniel A Pollyea 1, Courtney D DiNardo 2, Stéphane de Botton 3, Eytan M Stein
More informationNovel Induction and Targeted Strategies in Acute Myeloid Leukemia
Novel Induction and Targeted Strategies in Acute Myeloid Leukemia Eytan M. Stein, MD Leukemia Service Memorial Sloan Kettering Cancer Center Weill Cornell Medical College New York, New York Current Paradigms
More informationSafety and Efficacy of Venetoclax Plus Low-Dose Cytarabine in Treatment-Naïve Patients Aged 65 Years With Acute Myeloid Leukemia
Safety and Efficacy of Venetoclax Plus Low-Dose Cytarabine in Treatment-Naïve Patients Aged 65 Years With Acute Myeloid Leukemia Abstract 102 Wei AH, Strickland SA, Roboz GJ, Hou J-Z, Fiedler W, Lin TL,
More informationAll patients with FLT3 mutant AML should receive midostaurin-based induction therapy. Not so fast!
All patients with FLT3 mutant AML should receive midostaurin-based induction therapy Not so fast! Harry P. Erba, M.D., Ph.D. Professor, Internal Medicine Director, Hematologic Malignancy Program University
More informationUpdates in the Management of Acute Myeloid Leukemia
Updates in the Management of Acute Myeloid Leukemia Lydia Benitez, harmd, BCO 2017 TOA Conference I have no conflicts of interest with relation to the content of this presentation 4 Objectives Describe
More informationSummary of Key AML Abstracts Presented at the American Society of Hematology (ASH) December 2-6, San Diego CA
Summary of Key AML Abstracts Presented at the American Society of Hematology (ASH) December 2-6, 2016 - San Diego CA ASH 2016 ANNUAL MEETING: ABSTRACT SEARCH PAGE: https://ash.confex.com/ash/2016/webprogram/start.html
More informationAcute Myeloid and Lymphoid Leukemias
Acute Myeloid and Lymphoid Leukemias Hugo F. Fernandez, MD Department of Malignant Hematology & Cellular Therapy Moffitt at Memorial Healthcare System April 29, 2018 15 th Annual Miami Cancer Meeting Objectives
More informationESTABLISHED AND EMERGING THERAPIES FOR ACUTE MYELOID LEUKAEMIA. Dr Rob Sellar UCL Cancer Institute, London, UK
ESTABLISHED AND EMERGING THERAPIES FOR ACUTE MYELOID LEUKAEMIA Dr Rob Sellar UCL Cancer Institute, London, UK OVERVIEW Main focus on patients fit for intensive treatment Biological and Clinical Heterogeneity
More informationDepartment of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, Texas; 2 Sunesis Pharmaceuticals, Inc, South San Francisco
Phase I/II Study of Vosaroxin and Decitabine in Newly Diagnosed Older Patients with Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS) Naval Daver 1, Hagop Kantarjian 1, Guillermo
More informationANCO Hematological Malignancies Update: The year in review. Midostaurin Vyxeos Gemtuzumab ozogamicin Enasidenib. The year in preview
ANCO Hematological Malignancies Update: Gabriel Mannis, MD Assistant Professor, and Marrow Co-Director, Cancer Immunotherapy Clinic Acute Leukemia Sacramento, CA June 16, 2018 OVERVIEW Overview The year
More informationInotuzumab Ozogamicin in ALL. Hagop Kantarjian M.D. May 2016 Bologna, Italy
Inotuzumab Ozogamicin in ALL Hagop Kantarjian M.D. May 2016 Bologna, Italy Immuno Oncology in ALL Monoclonals + cytotoxic agents e.g.inotuzumab Bispecific monoclonals (CD3 + CD19) e.g.blinatumomab Modified
More informationAML in elderly. D.Selleslag AZ Sint-Jan Brugge, Belgium 14 December 2013
AML in elderly D.Selleslag AZ Sint-Jan Brugge, Belgium 14 December 2013 AML is predominantly a disease of the elderly incidence 2 3/100.000 SEER Cancer Statistics, National Cancer Institute, USA 2002 2006
More informationMolecularly Targeted Therapies - Strategies of the AMLSG
Molecularly Targeted Therapies - Strategies of the AMLSG Richard Schlenk Department of Internal Medicine III Ulm University, Germany Genotype-adapted Leukemia Program NAPOLEON GIMEMA/AMLSG/SAL APL [t(15;17)]
More informationRisk-adapted therapy of AML in younger adults. Sergio Amadori Tor Vergata University Hospital Rome
Risk-adapted therapy of AML in younger adults Sergio Amadori Tor Vergata University Hospital Rome Pescara 11/2010 AML: treatment outcome Age CR % ED % DFS % OS %
More informationEvolving Targeted Management of Acute Myeloid Leukemia
Evolving Targeted Management of Acute Myeloid Leukemia Jessica Altman, MD Robert H. Lurie Comprehensive Cancer Center of Northwestern University Learning Objectives Identify which mutations should be assessed
More informationPresented at the 58 th American Society of Hematology Annual Meeting and Exposition, December 5, 2016, San Diego, CA
1070 Determination of IDH1 mutational burden and clearance via next-generation sequencing in patients with IDH1 mutation-positive hematologic malignancies receiving AG-120, a first-in-class inhibitor of
More informationAcute Myeloid Leukemia: Targets and Curability, so Close But a Journey So Far
Acute Myeloid Leukemia: Targets and Curability, so Close But a Journey So Far Martin S. Tallman, M.D. Chief, Leukemia Service Memorial Sloan Kettering Cancer Center Professor of Medicine Weill Cornell
More informationANCO: ASCO Highlights 2018 Hematologic Malignancies
ANCO: ASCO Highlights 2018 Hematologic Malignancies Brian A. Jonas, M.D., Ph.D. UC Davis Comprehensive Cancer Center August 25, 2018 Brian Jonas, MD, PhD ANCO: ASCO Highlights 2018 Relevant financial relationships
More informationDepartment of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, Texas; 2 Sunesis Pharmaceuticals, Inc, South San Francisco
Phase I/II Study of Vosaroxin and Decitabine in Newly Diagnosed Older Patients with Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS) Naval Daver 1, Hagop Kantarjian 1, Guillermo
More informationANCO 2015: Treatment advances in acute leukemia
ANCO 2015: Treatment advances in acute leukemia Michaela Liedtke, MD Stanford, CA September 12, 2015!" Disclosures Research Support/P.I. Employee Consultant Major Stockholder Speakers Bureau Steering Committee
More informationLeukemia. Andre C. Schuh. Princess Margaret Cancer Centre Toronto
Leukemia Andre C. Schuh Princess Margaret Cancer Centre Toronto AGENDA Ø Overview Ø Key News This Year Ø Key News out of ASH 2016 Sessions Abstracts Ø Canadian Perspective Ø Overview 2015- Stone, R. et
More informationDisclosure Slide. Research Support: Onconova Therapeutics, Celgene
Oral Rigosertib Combined with Azacitidine in Patients with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS): Effects in Treatment Naïve and Relapsed- Refractory Patients Shyamala C. Navada,
More informationBest of ASH: Acute leukemia. Frédéric Baron
Best of ASH: Acute leukemia Frédéric Baron I Acute Myeloid Leukemia Flt3 inhibitors (ratify, sorafenib after HCT) 5 other important abstracts (in brief) Mutated genes in AML FLT3: The Cancer Genome Atlas
More informationRemission induction in acute myeloid leukemia
Int J Hematol (2012) 96:164 170 DOI 10.1007/s12185-012-1121-y PROGRESS IN HEMATOLOGY How to improve the outcome of adult acute myeloid leukemia? Remission induction in acute myeloid leukemia Eytan M. Stein
More informationDr Shankara Paneesha. ASH Highlights Department of Haematology & Stem cell Transplantation
ASH Highlights 2015 Themes of ASH 2015 Novel therapies - Myeloma AML Lymphoma Pd-L1 & PD-l inhibitors Emerging concepts in biology HIF-1a pathway Cautionary tales ASH Choosing Wisely list IFM/DFCI
More information2 Workshop Nazionale SIES Ematologia Traslazionale Nuovi Farmaci e Strategie Terapeutiche nelle LMA
2 Workshop Nazionale SIES Ematologia Traslazionale Nuovi Farmaci e Strategie Terapeutiche nelle LMA Adriano Venditti Ematologia Universita Tor Vergata, Roma Current Treatment Results in AML AGE, y CR%
More informationUpdates in Treatment Strategies for Acute Leukemia. Alexander Perl, MD Assistant Professor, Hematology/Oncology University of Pennsylvania 1/22/2016
Updates in Treatment Strategies for Acute Leukemia Alexander Perl, MD Assistant Professor, Hematology/Oncology University of Pennsylvania 1/22/2016 What is happening to standard of care in 2017? AML treatment
More informationHematologic Malignancies: Top Ten Advances Impacting Clinical Practice
Hematologic Malignancies: Top Ten Advances Impacting Clinical Practice Adam D. Cohen, MD Abramson Cancer Center University of Pennsylvania June 14, 2018 Please note that some of the studies reported in
More informationMeet-the-Expert: AML Treating older patients with AML
Meet-the-Expert: AML Treating older patients with AML Sergio Amadori Tor Vergata University Hospital Rome Istanbul 2012 AML in older patients Poor prognosis Minority treated with intensive Cx Treatment
More informationCLINICAL STUDY REPORT SYNOPSIS
CLINICAL STUDY REPORT SYNOPSIS Document No.: EDMS-PSDB-5412862:2.0 Research & Development, L.L.C. Protocol No.: R115777-AML-301 Title of Study: A Randomized Study of Tipifarnib Versus Best Supportive Care
More informationAbstract 861. Stein AS, Topp MS, Kantarjian H, Gökbuget N, Bargou R, Litzow M, Rambaldi A, Ribera J-M, Zhang A, Zimmerman Z, Forman SJ
Treatment with Anti-CD19 BiTE Blinatumomab in Adult Patients With Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (R/R ALL) Post-Allogeneic Hematopoietic Stem Cell Transplantation Abstract
More informationScottish Medicines Consortium
Scottish Medicines Consortium azacitidine 100mg powder for suspension for injection (Vidaza ) No. (589/09) Celgene Ltd 05 March 2010 The Scottish Medicines Consortium (SMC) has completed its assessment
More informationCautionary Note Regarding Forward-Looking Statements
lndoximod Combined with Standard Induction Chemotherapy Is Well Tolerated and Induces a High Rate of Complete Remission with MRD-Negativity in Patients with Newly Diagnosed AML: Results from a Phase 1
More informationTreatment of Low-Blast Count AML. Maria Teresa Voso Dipartimento di Biomedicina e Prevenzione Università di Roma Tor Vergata
Treatment of Low-Blast Count AML Maria Teresa Voso Dipartimento di Biomedicina e Prevenzione Università di Roma Tor Vergata Definition of Low-Blast Count AML Blast counts 20-30%, or > 10%? v Retrospective
More informationEmerging Treatment Options for Myelodysplastic Syndromes
Emerging Treatment Options for Myelodysplastic Syndromes James K. Mangan, MD, PhD Assistant Professor of Clinical Medicine Abramson Cancer Center, University of Pennsylvania Please note that some of the
More informationCREDIT DESIGNATION STATEMENT
CME Information LEARNING OBJECTIVES Recall the dose-limiting toxicity and preliminary clinical response results with 14- and 21-day extended treatment schedules of daily oral azacitidine. Apply new research
More informationM Y ELO I D D I FFER ENTIATI O N OPENS UP THE POSSIBILITIES
IDHIFA (enasidenib) is indicated for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an
More informationThe Evolving Treatment Landscape in AML
The Evolving Treatment Landscape in AML Elias Jabbour, MD Associate Professor Section Chief, Acute Lymphocytic Leukemia Department of Leukemia Division of Cancer Medicine The University of Texas MD Anderson
More informationSubset Specific Therapy in High Risk Myeloid Malignancies. Are We Making Progress? Olatoyosi Odenike, MD. The University of Chicago
Subset Specific Therapy in High Risk Myeloid Malignancies. Are We Making Progress? Olatoyosi Odenike, MD The University of Chicago Disclosure Information 23 rd Annual Developmental Therapeutics Symposium
More informationPersonalized Therapy for Acute Myeloid Leukemia. Patrick Stiff MD Loyola University Medical Center
Personalized Therapy for Acute Myeloid Leukemia Patrick Stiff MD Loyola University Medical Center 708-327-3216 Major groups of Mutations in AML Targets for AML: Is this Achievable? Chronic Myeloid Leukemia:
More information5/21/2018. Disclosures. Objectives. Normal blood cells production. Bone marrow failure syndromes. Story of DNA
AML: Understanding your diagnosis and current and emerging treatments Nothing to disclose. Disclosures Mohammad Abu Zaid, MD Assistant Professor of Medicine Indiana University School of Medicine Indiana
More informationEmerging Treatment Options for Myelodysplastic Syndromes
Emerging Treatment Options for Myelodysplastic Syndromes James K. Mangan, MD, PhD Assistant Professor of Clinical Medicine Abramson Cancer Center, University of Pennsylvania Please note that some of the
More informationA Phase II Study of the Combination of Oral Rigosertib and Azacitidine in Patients with Myelodysplastic Syndromes (MDS)
A Phase II Study of the Combination of Oral Rigosertib and Azacitidine in Patients with Myelodysplastic Syndromes (MDS) Shyamala C. Navada, MD 1, Lewis R. Silverman, MD 1, Katherine Hearn, RN 2, Rosalie
More informationSUPPLEMENTARY FIG. S3. Kaplan Meier survival analysis followed with log-rank test of de novo acute myeloid leukemia patients selected by age <60, IA
Supplementary Data Supplementary Appendix A: Treatment Protocols Treatment protocols of 123 cases patients were treated with the protocols as follows: 110 patients received standard DA (daunorubicin 45
More informationHighlights in acute myeloid leukemia (AML): what is going to change?
29 Highlights in acute myeloid leukemia (AML): what is going to change? C. Graux, MD, PhD SUMMARY The decision making process in AML integrates clinical features, an increasing amount of genetic information
More informationTherapeutic landscape in AML
Therapeutic landscape in AML Andrew Wei 1955: From the sea to Ara-C Cryptotethya crypta Werner Bergman Robert Feeney Bergmann W. & Burke D. C. 1955. Marine products. The nucleosides of sponges. 3: Spongothymidine
More informationManufacturer: Wyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc.
Brand Name: Mylotarg Generic Name: gentuzumab ozogamicin Manufacturer: Wyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc. Drug Class: CD33-directed antibody-drug conjugate Uses: Labeled Uses: Newly-diagnosed
More informationAML IN OLDER PATIENTS Whenever possible, intensive induction therapy should be considered
AML IN OLDER PATIENTS Whenever possible, intensive induction therapy should be considered Charles A. Schiffer, M.D. Karmanos Cancer Institute Wayne State University School of Medicine Detroit, MI WHY ARE
More informationAcute Myeloid Leukemia
Acute Myeloid Leukemia Guido Marcucci, M.D. Director, Gehr Family Center for Leukemia Research Hematologic Malignancies and Stem Cell Transplantation Institute City of Hope Acute Myeloid Leukemia Gene
More informationOncology Highlights: Leukemia & Myelodysplastic Syndromes
Oncology Highlights: Leukemia & Myelodysplastic Syndromes Jorge Cortes, MD Department of Leukemia The University of Texas, M.D. Anderson Cancer Center Highlights of the Day Leukemia & MDS AML: The field
More informationObjectives. I do not have anything to disclose.
Treatment of APL Objectives I do not have anything to disclose. Objectives 1. Urgency of early recognition and treatment 2. Treatment based on risk stratification 3. Monitoring for relapse 4. Treatment
More informationRecent advances in the management of metastatic breast cancer in older adults
Recent advances in the management of metastatic breast cancer in older adults Laura Biganzoli Medical Oncology Dept New Hospital of Prato Istituto Toscano Tumori Italy Important recent advances in the
More informationAcute Leukemia From Precision Medicine to ImmunoRx
Acute Leukemia From Precision Medicine to ImmunoRx Hagop M. Kantarjian, MD Professor and Chair, Department of Leukemia Samsung Distinguished Leukemia Chair in Cancer Medicine The University of Texas MD
More informationN Engl J Med Volume 373(12): September 17, 2015
Review Article Acute Myeloid Leukemia Hartmut Döhner, M.D., Daniel J. Weisdorf, M.D., and Clara D. Bloomfield, M.D. N Engl J Med Volume 373(12):1136-1152 September 17, 2015 Acute Myeloid Leukemia Most
More informationIPSS Modified 7/27/2011. WHO-Based Prognostic Scoring System (WPSS)
Advances in MDS Treatment: What s on the Horizon? New Prognostic Models and Therapies Jason Gotlib, MD, MS Assistant Professor of Medicine (Hematology) Stanford Cancer Center AA&MDSIF July 3, 011 WHO-Based
More informationBendamustine is Effective Therapy in Patients with Rituximab-Refractory, Indolent B-Cell Non-Hodgkin Lymphoma
Bendamustine is Effective Therapy in Patients with Rituximab-Refractory, Indolent B-Cell Non-Hodgkin Lymphoma Kahl BS et al. Cancer 2010;116(1):106-14. Introduction > Bendamustine is a novel alkylating
More information2 nd Generation TKI Frontline Therapy in CML
2 nd Generation TKI Frontline Therapy in CML Elias Jabbour, M.D. April 212 New York Frontline Therapy of CML in 212 - imatinib 4 mg daily - nilotinib 3 mg BID - dasatinib 1 mg daily Second / third line
More informationmidostaurin should be extended to patients who are deemed fit to receive intensive induction and consolidation, regardless of age.
midostaurin should be extended to patients who are deemed fit to receive intensive induction and consolidation, regardless of age. perc deliberated on the toxicity profile of midostaurin and noted that
More informationDisclosure. Study was sponsored by Karyopharm Therapeutics No financial relationships to disclose Other disclosures:
Combination of Selinexor with High-Dose Cytarabine and Mitoxantrone for Remission Induction in Acute Myeloid Leukemia is Feasible and Tolerable A Phase I Study (NCT02573363) Amy Y. Wang, Howie Weiner,
More informationLa lenalidomide: meccanismo d azione e risultati terapeutici. F. Ferrara
La lenalidomide: meccanismo d azione e risultati terapeutici F. Ferrara MDS: new treatment goals Emerging treatment options expected to facilitate shift from supportive care to active therapy in MDS New
More informationWelcome & Introductions. Dr. Steensma s slides are available for download at
What s on the Horizon for Acute Myeloid Leukemia? Welcome & Introductions Dr. Steensma s slides are available for download at www.lls.org/programs. 1 What s on the Horizon for Acute Myeloid Leukemia? What
More informationW Fiedler 1, M Heuser 2, J Chromik 3, F Thol 2, C Bokemeyer 1, S Theile 4, I Lebkuechner 4, AL Kranich 5
SAIL: Phase II Results of Ara-c and Idarubicin in Combina;on with the Selec;ve Inhibitor of Nuclear Export (SINE ) Compound Selinexor (KPT-330) in Pa;ents with Relapsed or Refractory AML W Fiedler 1, M
More information(212) (347)
EMBARGOED FOR MONDAY, JUNE 21, 2010: 3:00 P.M. EST For immediate release: June 21, 2010 Media Contact: Curtis Allen (212) 733-2096 (347) 443-5252 Investors Contact: Suzanne Harnett (212) 733-8009 Pfizer
More informationTreating AML: Other Molecular Targets. Richard A. Larson, MD The University of Chicago September 2017
Treating AML: Other Molecular Targets Richard A. Larson, MD The University of Chicago September 2017 Disclosures Richard A. Larson, MD Research funding to the University of Chicago: Astellas Celgene Daiichi
More informationMaintaining Long-Term Efficacy in the Elderly MDS Patient with Poor Performance Status
Hi, my name is Dr. Hetty Carraway. I am a staff physician at the Taussig Cancer Institute at the Cleveland Clinic. Welcome to Managing MDS. 1 As you all are aware, many of our patients with MDS are in
More informationOn behalf of Study SGI Investigators Team
Long Term Survival and Clinical Complete Responses of Various Prognostic Subgroups in 103 Relapsed/Refractory Acute Myeloid Leukemia (r/r AML) Patients Treated with Guadecitabine (SGI-110) in Phase 2 Studies
More informationHighlights in acute leukemia
CONGRESS HIGHLIGHTS 28 Highlights in acute leukemia T. Feys, MSc, MBA SPECIAL EDITION There has been a long period of time without any new acute myeloid leukemia (AML) treatments. However, the tide has
More informationLow Risk MDS Scoring System. Prognosis in Low Risk MDS. LR-PSS Validation 9/19/2012
Advances in MDS What s on the Horizon Tapan M. Kadia, MD Department of Leukemia MD Anderson Cancer Center Outline Newer Prognostic Systems Hypomethylating agent failures Newer Treatment approaches Role
More informationASCO 2009 Leukemia MDS -Transplant
ASCO 2009 Leukemia MDS -Transplant Ruben A. Mesa, MD Professor of Medicine Mayo Clinic College of Medicine Scottsdale, AZ, USA mesa.ruben@mayo.edu American Society of Hematology State-of-the-Art Symposium
More informationAmerican Society of Hematology Annual Meeting, San Diego, CA USA, 2 Dec 2018
Uproleselan (GMI-1271), an E-selectin antagonist, improves efficacy and safety of chemotherapy in R/R and newly diagnosed older patients with AML: final, correlative, and subgroup analyses Daniel J. DeAngelo,
More informationNational Institute for Health and Care Excellence. Single Technology Appraisal (STA)
Single Technology Appraisal (STA) Gemtuzumab ozogamacin for untreated de novo acute myeloid leukaemia Response to consultee and commentator comments re-scope Please note: Comments received in the course
More informationChemotherapy for Advanced Gastric Cancer
Chemotherapy for Advanced Gastric Cancer Andrés Cervantes Professor of Medicine DISCLOSURE OF INTEREST Employment: None Consultant or Advisory Role: Merck Serono, Roche, Beigene, Bayer, Servier, Lilly,
More information39% Treated. 61% Untreated. 33% UnRx. 45% UnRx. 59% UnRx. 80% UnRx
AML in the Elderly สน น ว ส ทธ ศ กด ช ย งานประช มว ชาการกลางป สมาคมโลห ตว ทยาแห งประเทศไทย คร งท 53 25-26 ต ลาคม 2561 ณ โรงแรมเลอ เมอร เด ยน เช ยงใหม จ งหว ดเช ยงใหม 33% UnRx 45% UnRx 59% UnRx 80% UnRx
More informationTargeted Agents as Maintenance Therapy. Karen Kelly, MD Professor of Medicine UC Davis Cancer Center
Targeted Agents as Maintenance Therapy Karen Kelly, MD Professor of Medicine UC Davis Cancer Center Disclosures Genentech Advisory Board Maintenance Therapy Defined Treatment Non-Progressing Patients Drug
More informationHighlights in Acute Myeloid Leukemia From the 2017 American Society of Hematology Annual Meeting and Exposition
March 2018 Volume 16, Issue 3, Supplement 8 A SPECIAL MEETING REVIEW EDITION Highlights in Acute Myeloid Leukemia From the 2017 American Society of Hematology Annual Meeting and Exposition A Review of
More informationUnderstanding AML Casey O Connell, MD Associate Professor, Jane Anne Nohl Division of Hematology Keck School of Medicine, USC
First Let s Look at Our Blood Understanding AML Casey O Connell, MD Associate Professor, Jane Anne Nohl Division of Hematology Keck School of Medicine, USC Bone Marrow: The Blood Cell Factory 10,000,000,000
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: TAG IDAG Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationBackground. Approved by FDA and EMEA for CLL and allows for treatment without chemotherapy in all lines of therapy
Updated Efficacy and Safety From the Phase 3 RESONATE-2 Study: Ibrutinib As First-Line Treatment Option in Patients 65 Years and Older With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Abstract
More informationTreating Higher-Risk MDS. Case presentation. Defining higher risk MDS. IPSS WHO IPSS: WPSS MD Anderson PSS
Treating Higher-Risk MDS Eyal Attar, M.D. Massachusetts General Hospital Cancer Center eattar@partners.org 617-724-1124 Case presentation 72 year old man, prior acoustic neuroma WBC (X10 3 /ul) 11/08 12/08
More informationUpdate: Chronic Lymphocytic Leukemia
ASH 2008 Update: Chronic Lymphocytic Leukemia Improving Patient Response to Treatment with the Addition of Rituximab to Fludarabine-Cyclophosphamide ASH 2008: Update on chronic lymphocytic leukemia CLL-8
More informationChemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC)
Chemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC) Jeffrey Crawford, MD George Barth Geller Professor for Research in Cancer Co-Program Leader, Solid Tumor Therapeutics Program
More informationImpact of Biomarkers in the Management of Patients with Acute Myeloid Leukemia
Impact of Biomarkers in the Management of Patients with Acute Myeloid Leukemia Hartmut Döhner Medical Director, Department of Internal Medicine III Director, Comprehensive Cancer Center Ulm Ulm University,
More informationEmerging Therapeutics in Hematologic Malignancies
Emerging Therapeutics in Hematologic Malignancies Brian A. Jonas, MD, PhD Assistant Professor of Medicine UC Davis Comprehensive Cancer Center September 26, 2015 16th Annual Advances in Oncology 2015 September
More informationMyelodysplastic Syndromes. Post-ASH meeting 2014 Marie-Christiane Vekemans
Myelodysplastic Syndromes Post-ASH meeting 2014 Marie-Christiane Vekemans Agenda New biological developments Risk assessment and prognostic factors New therapeutic options Agenda New biological developments
More informationNew treatment strategies in myelodysplastic syndromes and acute myeloid leukemia van der Helm, Lidia Henrieke
University of Groningen New treatment strategies in myelodysplastic syndromes and acute myeloid leukemia van der Helm, Lidia Henrieke IMPORTANT NOTE: You are advised to consult the publisher's version
More information